Eribulin Mesylate
Eribulin mesylate is a type of chemotherapy drug called an antimicrotubule agent. It is a laboratory-made version of a natural product called halichondrin B. It works by disrupting microtubules (cellular structures that help move chromosomes during mitosis). It blocks cell growth by stopping mitosis (cell division) and causes cells to die.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Eribulin mesylate is approved to treat:
- Breast cancer that has metastasized (spread to other parts of the body). It is used in patients who have already been treated with at least 2 types of chemotherapy for metastatic cancer, including an anthracycline and a taxane.
- Liposarcoma (a type of soft tissue sarcoma) that cannot be removed by surgery or has metastasized. It is used in patients who have already been treated with anthracycline chemotherapy.
Eribulin mesylate is also being studied in the treatment of other types of cancer.
More About Eribulin Mesylate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Eribulin Mesylate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Eribulin Mesylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.